Cartesian Therapeutics
RNAC
66 hedge funds and large institutions have $66.5M invested in Cartesian Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 14 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
0.75% less ownership
Funds ownership: 25.41% → 24.66% (-0.75%)
8% less funds holding
Funds holding: 72 → 66 (-6)
23% less capital invested
Capital invested by funds: $86.7M → $66.5M (-$20.2M)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$735K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$469K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$440K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$264K |
| 5 |
Renaissance Technologies
New York
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.01M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.12M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$281K |
| 4 |
AA
ALPS Advisors
Denver,
Colorado
|
-$256K |
| 5 |
Goldman Sachs
New York
|
-$208K |
RNAC Hedge Fund Activity: Q2 2025 in Review
66 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2025, worth a combined $66.5M — down 23% from $86.7M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RNAC and 8 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 22 added.
The largest buyer was 683 Capital Management, adding an estimated $735K. The largest seller was JP Morgan Chase, cutting an estimated $2.01M.
- 66 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2025, down from 72 in Q1 2025.
- Funds reported $66.5M of Cartesian Therapeutics stock for Q2 2025, down 23% quarter-over-quarter.
- 8 funds opened new Cartesian Therapeutics positions in Q2 2025 and 14 closed out, a net change of -6 holders.
- The largest Cartesian Therapeutics buyer in Q2 2025 was 683 Capital Management, an estimated $735K added.
- The largest Cartesian Therapeutics seller in Q2 2025 was JP Morgan Chase, an estimated $2.01M sold.
Based on aggregated 13F filings for Q2 2025.